Drug
Thrombolytic
Thrombolytic is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Withdrawn1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (50.0%)
N/A1 (50.0%)
Trials by Status
unknown133%
withdrawn133%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_4
Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
NCT05493163
withdrawn
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT03267199
unknownnot_applicable
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
NCT05354128
Clinical Trials (3)
Showing 3 of 3 trials
NCT05493163Phase 4
Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism
NCT03267199
The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI
NCT05354128Not Applicable
Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3